Thymoquinone regulates gene expression levels in the estrogen metabolic and interferon pathways in MCF7 breast cancer cells

Motaghed,Marjaneh; Al-Hassan,Faisal  Muti; Hamid,Shahrul  Sahul

doi:10.3892/ijmm.2013.1563

Thymoquinone regulates gene expression levels in the estrogen metabolic and interferon pathways in MCF7 breast cancer cells

Authors:
- Marjaneh Motaghed
- Faisal Muti Al-Hassan
- Shahrul Sahul Hamid
View Affiliations

Affiliations: Oncology and Radiological Science Cluster, Advanced Medical and Dental Institute, Universiti Sains Malaysia, Kepala Batas, Penang 13200, Malaysia
Published online on: November 21, 2013 https://doi.org/10.3892/ijmm.2013.1563
Pages: 8-16
Copyright: © Motaghed et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

New drugs are continuously being developed for the treatment of patients with estrogen receptor-positive breast cancer. Thymoquinone is one of the drugs that exhibits anticancer characteristics based on in vivo and in vitro models. This study further investigates the effects of thymoquinone on human gene expression using cDNA microarray technology. The quantification of RNA samples was carried out using an Agilent 2100 Bioanalyser to determine the RNA integrity number (RIN). The Agilent Low Input Quick Amplification Labelling kit was used to generate cRNA in two-color microarray analysis. Samples with RIN >9.0 were used in this study. The universal human reference RNA was used as the common reference. The samples were labelled with cyanine-3 (cye-3) CTP dye and the universal human reference was labelled with cyanine-5 (cye-5) CTP dye. cRNA was purified with the RNeasy Plus Mini kit and quantified using a NanoDrop 2000c spectrophotometer. The arrays were scanned data analysed using Feature Extraction and GeneSpring software. Two-step qRT-PCR was selected to determine the relative gene expression using the High Capacity RNA-to-cDNA kit. The results from Gene Ontology (GO) analysis, indicated that 8 GO terms were related to biological processes (84%) and molecular functions (16%). A total of 577 entities showed >2-fold change in expression. Of these entities, 45.2% showed an upregulation and 54.7% showed a downregulation in expression. The interpretation of single experiment analysis (SEA) revealed that the cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) and UDP glucuronosyltransferase 1 family, polypeptide A8 (UGT1A8) genes in the estrogen metabolic pathway were downregulated significantly by 43- and 11‑fold, respectively. The solute carrier family 7 (anionic amino acid transporter light chain, xc-system), member 11 (SLC7A11) gene in the interferon pathway, reported to be involved in the development of chemoresistance, was downregulated by 15‑fold. The interferon-induced protein with tetratricopeptide repeats (IFIT)1, IFIT2, IFIT3, interferon, α-inducible protein (IFI)6 (also known as G1P3), interferon regulatory factor 9 (IRF9, ISGF3), 2'-5'-oligoadenylate synthetase 1, 40/46 kDa (OAS1) and signal transducer and activator of transcription 1 (STAT1) genes all showed changes in expression following treatment with thymoquinone. The caspase 10, apoptosis-related cysteine peptidase (CASP10) gene was activated and the protein tyrosine phosphatase, receptor type, R (PTPRR) and myocyte enhancer factor 2C (MEF2C) genes were upregulated in the classical MAPK and p38 MAPK pathways. These findings indicate that thymquinone targets specific genes in the estrogen metabolic and interferon pathways.

View Figures

View References

1	IARC. World Cancer Report. Geneva: World Health Organization; Lyon: 2008, http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php.
2	Banerjee S, Azmi AS, Padhye S, et al: Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer. Pharm Res. 27:1146–1158. 2010. View Article : Google Scholar : PubMed/NCBI
3	Woo C, Loo SY, Gee V, et al: Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-gamma pathway. Biochem Pharmacol. 82:464–475. 2011. View Article : Google Scholar : PubMed/NCBI
4	Gali-Muhtasib H, Diab-Assaf M, Boltze C, Al-Hmaira J, Hartig R, Roessner A and Schneider-Stock R: Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol. 25:857–866. 2004.PubMed/NCBI
5	El-Mahdy MA, Zhu Q, Wang QE, Wani G and Wani AA: Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myoloblastic leukemia HL-60 cells. Int J Cancer. 117:409–417. 2005. View Article : Google Scholar : PubMed/NCBI
6	Rugo HS: The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol. 19:16–27. 2007. View Article : Google Scholar
7	Fisher B, Costantino JP, Wickerham DL, et al: Tamoifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 90:1371–1388. 1998. View Article : Google Scholar : PubMed/NCBI
8	Jordan VC: Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nat Rev. 7:46–53. 2007. View Article : Google Scholar : PubMed/NCBI
9	Duursen MB: Estrogen metabolizing enzymes: biomarkers of exposure, effect and susceptibility for carcinogenesis (Dissertation). Proefschrift Universiteit Utrecht Press; 2005
10	de Padua Mansur A, Silva TC, Takada JY, et al: Long-term prospective study of the influence of estrone levels on events in postmenopausal women with or at high risk for coronary artery disease. ScientificWorldJournal. 2012:3635952012.PubMed/NCBI
11	Zhou J and Seidel E: Estrogens induce visfatin expression in 3T3-L1 cells. Peptides. 31:271–274. 2010. View Article : Google Scholar : PubMed/NCBI
12	Abrahamsson A, Morad V, Saarinen N and Dabrosin C: Estradiol, tamoxifen, and flaxseed alter IL-1beta and IL-1Ra levels in normal human breast tissue in vivo. J Clin Endocrinol Metab. 97:E2044–E2054. 2012. View Article : Google Scholar : PubMed/NCBI
13	Androutsopoulos VP, Tsatsakis AM and Spandidos DA: Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer. 9:1872009. View Article : Google Scholar : PubMed/NCBI
14	Furukawa M, Nishimura M, Ogino D, et al: Cytochrome p450 gene expression levels in peripheral blood mononuclear cells in comparison with the liver. Cancer Sci. 95:520–529. 2004. View Article : Google Scholar : PubMed/NCBI
15	Fu J, Weise A, Falany J, et al: Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression. Breast Cancer Res Treat. 120:35–45. 2010. View Article : Google Scholar : PubMed/NCBI
16	Zhao YN, Zhang W, Chen YC, Fang F and Liu XQ: Relative imbalances in the expression of catechol-O-methyltransferase and cytochrome P450 in breast cancer tissue and their association with breast carcinoma. Maturitas. 72:139–145. 2012.PubMed/NCBI
17	Gajjar KL, Martin-hirsch PL and Martin FL: CYP1B1 and hormone-induced cancer. Cancer Lett. 324:13–30. 2012. View Article : Google Scholar : PubMed/NCBI
18	Mikstack R, Rimando AM, Dutkiewicz Z, Stefanski T and Sobiak S: Design, synthesis and evaluation of the inhibitory selectivity of novel transresveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1. Bioorg Med Chem. 20:5117–6126. 2012. View Article : Google Scholar : PubMed/NCBI
19	Ashley-Martin J, Vanleeuwen J, Cribb A, Andreou P and Guernsey JR: Breast cancer risk, fungicide exposure and CYP1A1^*2A gene-environment interactions in a province-wide case control study in Prince Edward Island, Canada. Int J Environ Res Publ Health. 9:1846–1858. 2012.PubMed/NCBI
20	Williams-Brown MY, Salih SM and Xu X: The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol. 126:78–86. 2012. View Article : Google Scholar : PubMed/NCBI
21	Scornaienchi ML, Thornton C, Willett KL and Wilson JY: Cytochrome P450-mediated 17b-estradiol metabolism in zebrafish (Danio rerio). J Endocrinol. 206:317–325. 2010. View Article : Google Scholar : PubMed/NCBI
22	Han EH, Kim HG, Hwang YP, Song GY and Jeong HG: Prostaglandin E2 induces CYP1B1 expression via ligand-independent activation of the ERalpha pathway in human breast cancer cells. Toxicol Sci. 114:204–216. 2010. View Article : Google Scholar : PubMed/NCBI
23	Guengerich PF, Chun Y, Kim D, Gillam E and Shimada T: Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res. 523–524:173–182. 2003.PubMed/NCBI
24	Zahid M, Kohli E, Saeed M, Rogan E and Cavalieri E: The greater reactivity of estradiol-3,4-quinone vs estradiol-2,3-quinone with DNA in the formation of depurinating adducts: implications for tumor-initiating activity. Chem Res Toxicol. 19:164–172. 2006. View Article : Google Scholar : PubMed/NCBI
25	Lakhani NJ, Sarkar MA, Venitz J and Figg WD: 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy. 23:165–172. 2003. View Article : Google Scholar : PubMed/NCBI
26	Newman SP, Foster PA, Stengel C, et al: STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res. 14:597–606. 2008. View Article : Google Scholar : PubMed/NCBI
27	Verenich S and Gerk PM: Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges. Mol Pharm. 7:2030–2039. 2010. View Article : Google Scholar : PubMed/NCBI
28	Huang Y, Dai Z, Barbacioru C and Sadee W: Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 65:7446–7454. 2005. View Article : Google Scholar : PubMed/NCBI
29	Krishna R and Mayer LD: Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 11:265–283. 2000. View Article : Google Scholar : PubMed/NCBI
30	Weichselbaum RR, Ishwaran HYT, Nuyten DSA, et al: An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc Natl Acad Sci USA. 105:18490–18495. 2008. View Article : Google Scholar : PubMed/NCBI
31	Luker KE, Pica CM, Schreiber RD and Piwnica-Worms SD: Overexpression of IRF9 confers resistance to antimicrotubule agents in breast cancer cells. Cancer Res. 61:6540–6547. 2001.PubMed/NCBI
32	Camaj P, Ischenko I, Seeliger H, Arnold G, Jauch KW and Bruns CJ: Overexpression of the gene IFIT3 enhances tumor growth, angiogenesis, metastasing and chemoresistance of the pancreas carcinoma cells. In: Chirurgisches Forum und DGAV Forum; 2009; 38. Springer; Berlin Heidelberg: pp. 17–18. 2009
33	Cheriyath V, Kuhns MA, Jacobs BS, et al: G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer. Oncogene. 31:2222–2236. 2012. View Article : Google Scholar : PubMed/NCBI
34	Veals SA, Schindler C, Leonard D, Fu XY, Aebersold R, Darnell JE Jr and Levy DE: Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol Cell Biol. 12:3315–3324. 1992.
35	Wong LH, Hatzinisiriou I, Devenish RJ and Ralph SJ: IFN-γ priming up-regulates IFN-stimulated gene factor 3 (ISGF3) components, augmenting responsiveness of IFN-resistant melanoma cells to type I IFNs. J Immunol. 160:5475–5484. 1998.
36	Englert NA, Spink BC and Spink DC: Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells. J Steroid Biochem Mol Biol. 123:140–150. 2011. View Article : Google Scholar : PubMed/NCBI
37	Pham AN, Bower PE, Alvardo O, Ravula R, Gout PW and Huang Y: Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines. J Pharmacol Exp Ther. 323:949–958. 2010. View Article : Google Scholar : PubMed/NCBI
38	Lin G, Aranda V, Muthuswamy SK and Tonks NK: Identification of PTPN23 as a novel regulator of cell invasion in mammary epithelial cells from a loss-of-function screen of the ‘PTP-ome’. Genes Dev. 25:1412–1425. 2011.PubMed/NCBI
39	Su PH, Lin YW, Huang RL, et al: Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer. Oncogene. 32:15–26. 2012.PubMed/NCBI
40	Arafa el-SA, Zhu Q, Shah ZI, Wani G, Barakat BM, Racoma I, El-Mahdy MA and Wani AA: Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res. 706:28–35. 2011. View Article : Google Scholar : PubMed/NCBI